First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

NCT06063070 PHASE2 NOT_YET_RECRUITING

This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.

Details

Lead sponsor	Sun Yat-sen University
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	44
Start date	Wed Oct 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Oct 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Ovarian Cancer
• High Grade Serous Adenocarcinoma of Ovary
• High Grade Endometrioid Ovarian Cancer
• Primary Peritoneal Cancer
• Fallopian-tube Cancer

Interventions

• Fluzoparib Capsules
• Bevacizumab

Countries

China